endoscopic intestinal polypectomy
Conditions
Interventions
Group E1:Patients aged 18-65 years of Group E1 received intravenous injection of esketamine at a dose of 0.2mg/kg, and then administered propofol. After the patient loses consciousness and the lower j
Group E2:Patients aged 18-65 years of Group E2 received intravenous injection of esketamine at a dose of 0.3mg/kg, and then administered propofol. After the patient loses consciousness and the lower j
Group EO1 :Patients aged over 65 years of Group EO1 received intravenous injection of 0.2mg/kg esketamine, and then administered propofol. After the patient loses consciousness and the lower jaw rela
Group EO2:Patients aged over 65 years of Group EO2 received intravenous injection of 0.3 mg/kg esketamine, and then administered propofol. After the patient loses consciousness and the lower jaw rela
Sponsors
Beijing Friendship Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. American Society of Anesthesiologists (ASA) classification of grade I-III; 2. Age > 18 years; 3. BMI < 30 kg/m^2; 4. patients who need laryngeal mask general anesthesia for elective colonoscopy treatment (endoscopic submucosal dissection, endoscopic mucosal resection, and polypectomy); 5. informed consent, voluntary participation in the trial, and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with a history of allergy to propofol, esketamine or other anesthetic drugs; 2. Those with a history of severe heart, lung, brain, liver or kidney diseases; 3. Those with hypertension, glaucoma or elevated intracranial pressure; 4. Those with a history of central nervous system diseases, mental disorders, psychological disorders or preoperative cognitive dysfunction; 5. Those who have been taking sedative-hypnotic or sedative-analgesic drugs for a long time; 6. Patients with difficult airways, chronic obstructive pulmonary disease, acute upper respiratory tract infection, asthma attack or acute severe laryngeal diseases; 7. Those who refuse to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ED50, ED95; | — |
Secondary
| Measure | Time frame |
|---|---|
| MAP, HR, SpO2, RR at T0 (before anesthesia induction), T1 (after anesthesia induction), T2 (before tracheal tube insertion), T3 (1 minute after LMA insertion), T4 (at the end of the surgery), T5 (before removal of the LMA), and T6 (after removal of the LMA);Total dosage of propofol, duration of surgery, anesthesia awakening time (time from drug withdrawal to removal of LMA), and recovery time (time from entering the PACU to meeting the discharge criteria); | — |
Countries
China
Contacts
Public ContactHaixia Wang
Beijing Friendship Hospital, Capital Medical University
Outcome results
None listed